The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium

[1]  S. Schreiber,et al.  Vedolizumab induction therapy for inflammatory bowel disease in clinical practice – a nationwide consecutive German cohort study , 2016, Alimentary pharmacology & therapeutics.

[2]  Siddharth Singh,et al.  How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease , 2016, Inflammatory bowel diseases.

[3]  A. Ford,et al.  Systematic review with meta‐analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease , 2016, Alimentary pharmacology & therapeutics.

[4]  Chien-Huan Chen,et al.  Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice. , 2016, Journal of Crohn's & colitis.

[5]  M. Silverberg,et al.  A validated web‐based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables , 2016, Alimentary pharmacology & therapeutics.

[6]  N. Ding,et al.  Systematic review: predicting and optimising response to anti‐TNF therapy in Crohn's disease – algorithm for practical management , 2016, Alimentary pharmacology & therapeutics.

[7]  A. Ananthakrishnan,et al.  Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort , 2015, Inflammatory bowel diseases.

[8]  W. Sandborn,et al.  Pseudomonas Meningitis During Vedolizumab Therapy for Crohn’s Disease , 2015, The American Journal of Gastroenterology.

[9]  S. Vermeire,et al.  IOIBD technical review on endoscopic indices for Crohn's disease clinical trials , 2015, Gut.

[10]  G. D'Haens,et al.  Assessment of mucosal healing in inflammatory bowel disease: review. , 2015, Gastrointestinal endoscopy.

[11]  J. Gisbert,et al.  Systematic review with meta‐analysis: the efficacy of a second anti‐TNF in patients with inflammatory bowel disease whose previous anti‐TNF treatment has failed , 2015, Alimentary pharmacology & therapeutics.

[12]  G. Kaplan,et al.  Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. , 2015, Gastroenterology.

[13]  Zhen Wang,et al.  Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis. , 2014, Mayo Clinic proceedings.

[14]  S. Danese,et al.  Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. , 2014, Gastroenterology.

[15]  Heather B. Blunt,et al.  Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  P. Rutgeerts,et al.  Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. , 2014, Gastroenterology.

[17]  C. Siegel,et al.  The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease. , 2014, Gastroenterology clinics of North America.

[18]  C. Siegel,et al.  Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD , 2014, Gut.

[19]  O. Dewit,et al.  Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[20]  P. Rutgeerts,et al.  Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial , 2013, Gut.

[21]  Kristin Stephens,et al.  Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.

[22]  P. Rutgeerts,et al.  The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. , 2013, Gastroenterology.

[23]  D. Hommes,et al.  Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. , 2013, Journal of Crohn's & colitis.

[24]  G. Corazza,et al.  Effect of Tumor Necrosis Factor-&agr; Blockade on Mucosal Addressin Cell-adhesion Molecule-1 in Crohn's Disease , 2013, Inflammatory bowel diseases.

[25]  A. Kornbluth,et al.  Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[26]  H. Sokol,et al.  Current smoking differentially affects blood mononuclear cells from patients with crohn's disease and ulcerative colitis: Relevance to its adverse role in the disease , 2012, Inflammatory bowel diseases.

[27]  P. Rutgeerts,et al.  Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. , 2012, Gastroenterology.

[28]  M. Gazouli,et al.  Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. , 2010, Journal of Crohn's & colitis.

[29]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[30]  S. Pocock,et al.  Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, BMJ : British Medical Journal.

[31]  J. Satsangi,et al.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.

[32]  I. Hauser,et al.  Differential induction of VCAM-1 on human iliac venous and arterial endothelial cells and its role in adhesion. , 1993, Journal of immunology.

[33]  Erik von Elm,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. , 2014, International journal of surgery.